Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491267 | ||
| 003 | CHVBK | ||
| 005 | 20210128100509.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150801xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0755-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0755-6 | ||
| 245 | 0 | 0 | |a Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer |h [Elektronische Daten] |c [Yuichi Takiguchi, Shunichiro Iwasawa, Koichi Minato, Yosuke Miura, Akihiko Gemma, Rintaro Noro, Kozo Yoshimori, Masato Shingyoji, Mitsunori Hino, Masahiro Ando, Hiroaki Okamoto] |
| 520 | 3 | |a Purpose: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. Methods: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6mgh/L), docetaxel (60mg/m2), and bevacizumab (15mg/kg) on day 1, repeated every 3weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3weeks until disease progression or occurrence of predefined toxicity. The planned patient number was 40, and the primary endpoint was progression free survival (PFS) as assessed by independent reviewers. Results: One patient refused the treatment after enrollment; thus, 39 patients were treated and analyzed. The 3-drug therapy was delivered for a median of 4 cycles, and 54% of the patients proceeded to the maintenance therapy for a median of 4 cycles. The overall response rate was 74.4% (29/39), with a 95% confidence interval (CI) of 60.0 to 88.7%. The median PFS and overall survival (OS) were 6.2months (95% CI, 4.8-8.5months) and 22.4months (95% CI, 11.3-26.2months), respectively. Toxicities of grade 3 or higher included neutropenia in 71.8%, febrile neutropenia in 23.1%, and hypertension in 38.5% of the patients, but they were transient and manageable. Conclusion: The primary endpoint was met. The regimen yielded promising results with an excellent overall response rate, PFS, and OS for chemotherapy-naïve patients with advanced non-squamous NSCLC. Further studies are warranted. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Non-squamous |2 nationallicence | |
| 690 | 7 | |a Non-small cell lung carcinoma |2 nationallicence | |
| 690 | 7 | |a Bevacizumab |2 nationallicence | |
| 690 | 7 | |a Docetaxel |2 nationallicence | |
| 690 | 7 | |a Carboplatin |2 nationallicence | |
| 690 | 7 | |a Phase II study |2 nationallicence | |
| 700 | 1 | |a Takiguchi |D Yuichi |u Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, 260-8670, Chuo-ku, Chiba, Japan |4 aut | |
| 700 | 1 | |a Iwasawa |D Shunichiro |u Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, 260-8670, Chuo-ku, Chiba, Japan |4 aut | |
| 700 | 1 | |a Minato |D Koichi |u Department of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takabayashinishi, 373-8550, Ohta, Japan |4 aut | |
| 700 | 1 | |a Miura |D Yosuke |u Department of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takabayashinishi, 373-8550, Ohta, Japan |4 aut | |
| 700 | 1 | |a Gemma |D Akihiko |u Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, 113-8602, Bunnkyo-ku, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Noro |D Rintaro |u Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, 113-8602, Bunnkyo-ku, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yoshimori |D Kozo |u Department of Respiratory Medicine, Anti-tuberculosis Association Fukujuji Hospital, 3-1-24, Matsuyama, 204-8522, Kiyose, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Shingyoji |D Masato |u Department of Thoracic Disease, Chiba Cancer Center, 666-2, Nitona, 260-8717, Chuo-ku, Chiba, Japan |4 aut | |
| 700 | 1 | |a Hino |D Mitsunori |u Respiratory Disease Center, INBAHITEC Medical Center, Nippon Medical School Chiba Hokusoh Hospital, 1715, Kamagari, 270-1694, Inzai, Chiba, Japan |4 aut | |
| 700 | 1 | |a Ando |D Masahiro |u Division of Cancer Chemotherapy, Tsuboi Cancer Center Hospital, 1-10-13, Nagakubo, Azumi, 963-0197, Kouriyama, Japan |4 aut | |
| 700 | 1 | |a Okamoto |D Hiroaki |u Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, 56, Okazawa, Hodogaya-ku, 240-8555, Yokohama, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/4(2015-08-01), 659-667 |x 1341-9625 |q 20:4<659 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0755-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0755-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takiguchi |D Yuichi |u Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, 260-8670, Chuo-ku, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Iwasawa |D Shunichiro |u Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, 260-8670, Chuo-ku, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Minato |D Koichi |u Department of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takabayashinishi, 373-8550, Ohta, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Miura |D Yosuke |u Department of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takabayashinishi, 373-8550, Ohta, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Gemma |D Akihiko |u Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, 113-8602, Bunnkyo-ku, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Noro |D Rintaro |u Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, 113-8602, Bunnkyo-ku, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yoshimori |D Kozo |u Department of Respiratory Medicine, Anti-tuberculosis Association Fukujuji Hospital, 3-1-24, Matsuyama, 204-8522, Kiyose, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shingyoji |D Masato |u Department of Thoracic Disease, Chiba Cancer Center, 666-2, Nitona, 260-8717, Chuo-ku, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hino |D Mitsunori |u Respiratory Disease Center, INBAHITEC Medical Center, Nippon Medical School Chiba Hokusoh Hospital, 1715, Kamagari, 270-1694, Inzai, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ando |D Masahiro |u Division of Cancer Chemotherapy, Tsuboi Cancer Center Hospital, 1-10-13, Nagakubo, Azumi, 963-0197, Kouriyama, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Okamoto |D Hiroaki |u Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, 56, Okazawa, Hodogaya-ku, 240-8555, Yokohama, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/4(2015-08-01), 659-667 |x 1341-9625 |q 20:4<659 |1 2015 |2 20 |o 10147 | ||